Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Diagnostic Imaging in Relapsing Polychondritis With Atypical Manifestations

Honne, Kyoko; Nagashima, Takao; Onishi, Shun; Nagatani, Katsuya; Iwamoto, Masahiro; Minota, Seiji

doi:10.1097/rhu.0b013e31828635a9

Cited by 11 publications

(6 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings suggest that PET/CT is a promising radiological tool for monitoring the treatment response and disease progress. However, because there is no consensus about the duration of corticosteroid treatment, there is no consensus regarding the use of PET/CT to optimise corticosteroid strategies, although some reports have pointed to its potential value [9][10][11][12][13][14][15]. The time interval for PET/CT scans after corticosteroid therapy remains unclear, as it has been reported to range from 1 month to 13 months [9-11, 13, 18].…”

Section: Discussionmentioning

confidence: 99%

“…In 2007, Nishiyama et al [8] first described a case of RP diagnosed using fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT). Since then, a series of case reports have demonstrated that PET/ CT is capable of determining the distribution of all lesions and facilitating their early recognition, locating biopsy sites, and evaluating disease activity and the therapeutic response to treatment [9][10][11][12][13][14][15][16]. However, these were mostly single case reports, and there has been no comprehensive study focusing on the application of PET/CT in RP.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

WITHDRAWN: A re-evaluation of 18F-FDG PET/CT for diagnosing relapsing polychondritis and monitoring the therapeutic response to treatment

Wang¹,

Li²,

Chen³

et al. 2018

Oncotarget

View full text Add to dashboard Cite

Background: Relapsing polychondritis (RP) is a rare degenerative disease and its diagnosis is often delayed and difficult. Although the use of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT) for diagnosing RP has been reported previously, its true diagnostic value is uncertain due to the limited number of published case reports. Moreover, its value for biopsy guidance and therapeutic response monitoring remain controversial. Materials and Methods: Data on 30 patients with a clinical diagnosis of RP who underwent PET/CT scans were retrospectively reviewed. Follow-up scans were performed in 10 patients, and visual scores (VS) and maximal standard uptake (SUV max) values were analysed. Results: With the initial scan, 83.3% of patients showed lesions in more than one cartilage. Mean VS and SUV max values in the cartilages were 2.92 ± 0.38 and 4.06 ± 0.18, respectively. In 18 patients with no history of corticosteroid treatment, more cartilages were affected than in patients who previously received corticosteroids (3.89 ± 0.29 vs 2.75 ± 0.63, respectively; p = 0.07). Positive rates for PET/CT-guided biopsy in nasal, auricular and tracheal/bronchial cartilages were 100%, 88.9% and 10.5%, respectively. In comparison, the positive rate for non-PET/CT-guided biopsy of auricular cartilage was 92.3%. Compared with the initial scan, the second scan had significantly lower mean VS (1.41 ± 0.20 vs 2.92 ± 0.38, respectively; p < 0.0001) and SUVmax values (2.76 ± 0.14 vs 4.06 ± 0.18, respectively; p < 0.001). Conclusions: FDG uptake in multiple cartilages suggests a diagnosis of RP, but repeated administration of corticosteroids may undermine the diagnostic value of 18 F-FDG PET/CT. Further investigation of its use in locating biopsy sites and in monitoring the response to treatment is required.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: A re-evaluation of 18F-FDG PET/CT for diagnosing relapsing polychondritis and monitoring the therapeutic response to treatment

Wang¹,

Li²,

Chen³

et al. 2018

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Honne et al proposed fluorodeoxyglucosepositron emission tomography/computed tomography as a valuable diagnostic tool for the diagnosis and evaluation of a RPC patient, who had not typical ear and nose involvement. 26 Shimizu et al reported that inspiratory and expiratory three-dimensional computed tomography and impulse oscillation with three-dimensional color imaging may be used to evaluate the airway involvement in the RPC patients who can not perform (repeated) spirometry. 27 Due to rarity of RPC, there is no established therapy regiments.…”

Section: Discussionmentioning

confidence: 99%

Relapsing Polychondritis Misdiagnosed and Treated as a ''Soft Tissue Infection'' and a Brief Review of Diagnostic Clinical Clues

Gündüz¹,

Demirkan²,

Samav³

et al. 2017

Turkiye Klinikleri J Dermatol

View full text Add to dashboard Cite

“…A total of 18 articles [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] , involving 29 cases, were identi ed that reported the diagnosis of RP using PET/CT(Table 1). Thus, a total of 32 cases of RP, diagnosed using FDG PET/CT, have been reported, including the three cases described in the present study.…”

Section: Clinical Characteristics and Pet/ct Ndings On Casementioning

confidence: 99%

“…As of December 2019, the author searched the pubmed database for titles containing "relapsing polychondritis" and "PET/CT" or "PET-CT" keywords. A total of 19 related reports were detected, including 29 cases of RP [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] , indicating that it is still a rare disease. The reported cases are mostly clinical collapse of the bridge of the nose and auricle, when severe respiratory symptoms suggest cartilage involvement, or only when cartilage biopsy is performed.…”

Section: Clinical Characteristics and Pet/ct Ndings On Casementioning

confidence: 99%

Value of 18 F-FDG PET/CT for early diagnosis and treatment monitoring of relapsing polychondritis

Liu

Fan

Zhou

et al. 2023

Preprint

View full text Add to dashboard Cite

Relapsing polychondritis (RP) is a rare autoimmune disease. Few studies have reported the value of 18F-fluorodeoxyglucose positron emission-computed tomography (18F-FDG-PET/CT) for diagnosis, guiding biopsy and treatment monitoring of RP. 18F-FDG-PET/CT in assessing RP presenting fever of unknown origin (FUO) is not yet reported. To evaluate of 18F-fluorodeoxyglucose positron emission-computed tomography (18F-FDG-PET/CT) for early diagnosis, guiding biopsy and treatment monitoring of relapsing polychondritis (RP), especially for the patient of RP presenting FUO. Consistent with 32 cases had been underwent 18F-FDG-PET/CT scanning, which showed multiple moderately 18F-FDG uptake in the involvement of multiple organs, including the nose, throat, trachea, bronchi, cost cartilage and joint cartilages (SUVmax distribution was 1.93–13.03; mean, 5.02). 50% (16/32) patients were used for PET/CT re-examination after treatment, which revealed that 93.8% (15/16) of patients with RP had decreased obviously for 18F-FDG uptake, with 37.6% (6/16) in decreased substantially and 56.2% (9/16) for disappeared, respectively. The time to diagnosis in these cases was 4.2 months, obviously shorter than the average diagnosis time (20months), showing earlier than conventional method. In addition, biopsies were performed in 56.3% (18/32) of all patients; 94.4% (17/18) cases were positive, which showed useful for targeting biopsy sites. 62.5% (20/32) of all patients presenting FUO had been early diagnosed using 18F-FDG-PET/CT. Treatment monitoring of RP, especially for the patient presenting FUO. It is of great value for monitoring the activity of inflammatory, and guiding the selection of a biopsy site.

show abstract

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Diagnostic Imaging in Relapsing Polychondritis With Atypical Manifestations

Cited by 11 publications

References 3 publications

WITHDRAWN: A re-evaluation of 18F-FDG PET/CT for diagnosing relapsing polychondritis and monitoring the therapeutic response to treatment

WITHDRAWN: A re-evaluation of 18F-FDG PET/CT for diagnosing relapsing polychondritis and monitoring the therapeutic response to treatment

Relapsing Polychondritis Misdiagnosed and Treated as a ''Soft Tissue Infection'' and a Brief Review of Diagnostic Clinical Clues

Value of 18 F-FDG PET/CT for early diagnosis and treatment monitoring of relapsing polychondritis

Contact Info

Product

Resources

About